Akebia Therapeutics, Inc. - Common Stock (AKBA)
Frequently Asked Questions About Akebia Therapeutics, Inc. - Common Stock (AKBA)
Does Akebia engage in partnerships?
Yes, Akebia Therapeutics engages in strategic partnerships and collaborations with other biopharmaceutical companies, research institutions, and healthcare organizations. These partnerships often focus on co-developing therapies, enhancing research capabilities, and expanding market access for its products.
Has Akebia participated in any clinical trials?
Yes, Akebia Therapeutics has participated in numerous clinical trials, especially those focused on evaluating classic anemia indications and its lead candidate, vadadustat. These trials are essential for gathering scientific data on safety and effectiveness, which will support the drug approval process.
Has Akebia received FDA approval for any of its products?
As of now, Akebia Therapeutics has not yet received FDA approval for its lead product, vadadustat, but the company has completed significant clinical trials as part of the regulatory approval process. The results of these trials are critical for obtaining FDA clearance and bringing the drug to market.
How does Akebia approach sustainability?
Akebia Therapeutics is committed to sustainability in its operational practices and product development. The company strives to minimize environmental impact while maximizing healthcare benefits, focusing on ethical sourcing, waste reduction, and responsible resource management across its operations.
Is Akebia Therapeutics a publicly traded company?
Yes, Akebia Therapeutics, Inc. is a publicly traded company listed on the Nasdaq stock exchange under the ticker symbol AKBA. This allows investors to buy and sell shares of the company as part of the public market.
What are Akebia's main products?
Akebia Therapeutics' main product is vadadustat, an investigational oral HIF-PH inhibitor designed to treat anemia due to chronic kidney disease in both dialysis-dependent and non-dialysis-dependent patients. The company is also involved in developing other treatments targeting similar renal disorders.
What challenge does Akebia face in the market?
Akebia Therapeutics faces several challenges in the market, including intense competition from other biopharmaceutical companies developing anemia treatments for chronic kidney disease and the complexities associated with regulatory approval processes. Staying on the cutting edge of research and maintaining financial stability are also ongoing challenges.
What community or social initiatives does Akebia support?
Akebia Therapeutics is dedicated to enriching communities and improving patient care through various social initiatives. The company often engages in community health programs related to kidney health, supports educational efforts, and contributes to patient advocacy groups seeking to raise awareness of chronic kidney disease.
What does Akebia Therapeutics, Inc. do?
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for patients with kidney disease. The company's primary focus is on products that can improve the treatment of anemia related to chronic kidney disease (CKD), particularly supplements that enhance erythropoiesis or red blood cell production.
What is Akebia's clinical pipeline like?
Akebia Therapeutics has a robust clinical pipeline that focuses on its lead product, vadadustat, as well as other candidates aimed at addressing anemia due to chronic kidney disease. The company actively conducts clinical trials to evaluate the safety and efficacy of its products, engaging in various phases of development to bring therapies to market.
What is the financial condition of Akebia Therapeutics?
The financial condition of Akebia Therapeutics, like many biopharmaceutical companies, involves considerations of funding, revenue generation, research and development expenditures, and other operational costs. Investors closely watch the company’s quarterly earnings reports to assess its financial health and sustainability in pursuing its long-term objectives.
What is the future outlook for Akebia Therapeutics?
The future outlook for Akebia Therapeutics appears promising, with ongoing developments related to its clinical pipeline and increasing interest in treatments for chronic kidney disease. Success in obtaining regulatory approvals and expanding its product offerings could enhance the company's market position and growth potential.
What is the mission of Akebia Therapeutics?
The mission of Akebia Therapeutics is to improve the lives of patients suffering from kidney disease through innovative therapies. The company strives to advance the science of renal disease treatment by focusing on unique mechanisms of action and developing effective solutions for anemia management.
What is the ticker symbol for Akebia Therapeutics?
The ticker symbol for Akebia Therapeutics, Inc. is AKBA. It is traded on the Nasdaq stock exchange, where investors can buy and sell shares of the company's common stock.
What is vadadustat?
Vadadustat is an oral medication being studied by Akebia Therapeutics for the treatment of anemia associated with chronic kidney disease. It works by stabilizing the hypoxia-inducible factor (HIF), which can enhance the body's natural ability to produce erythropoietin, leading to increased red blood cell production.
What role does research and development play at Akebia?
Research and development (R&D) are pivotal to Akebia Therapeutics' strategy, as the company is committed to innovation in the treatment of kidney disease. R&D efforts focus on discovering new therapies, optimizing existing candidates, and ensuring that the company remains at the forefront of scientific advances in its field.
When was Akebia Therapeutics founded?
Akebia Therapeutics, Inc. was founded in 2010. The company was established to discover and develop novel therapies aimed specifically at treating chronic kidney disease and its associated complications.
Where is Akebia Therapeutics headquartered?
Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. The company's location in this biotech hub allows it to engage with a diverse network of scientists, healthcare professionals, and industry leaders.
Who are the key executives at Akebia Therapeutics?
The key executives at Akebia Therapeutics usually include the CEO, CFO, and other senior officers who oversee various departments such as research, clinical development, and commercial operations. These leaders work together to guide the company's strategic direction and ensure the development and delivery of effective therapies.
What is the current price of Akebia Therapeutics, Inc. - Common Stock?
The current price of Akebia Therapeutics, Inc. - Common Stock is 1.765
When was Akebia Therapeutics, Inc. - Common Stock last traded?
The last trade of Akebia Therapeutics, Inc. - Common Stock was at 2:55 pm EDT on April 4th, 2025
What is the market capitalization of Akebia Therapeutics, Inc. - Common Stock?
The market capitalization of Akebia Therapeutics, Inc. - Common Stock is 308.06M
How many shares of Akebia Therapeutics, Inc. - Common Stock are outstanding?
Akebia Therapeutics, Inc. - Common Stock has 174.54M shares outstanding.